Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 13/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 13/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30981057 | 0.85 | DDB1 (0.59) | DDB1CRBNGPR119 | |
| SCHEMBL21876868 | 0.82 | DDB1 (0.63) | DDB1CRBNGPR119PDK2 | |
| SCHEMBL31487496 | 0.82 | DDB1 (0.54) | DDB1CRBNGPR119 | |
| SCHEMBL30965659 | 0.82 | DDB1 (0.54) | DDB1CRBNGPR119 | |
| SCHEMBL21876964 | 0.82 | DDB1 (0.67) | DDB1CRBNGPR119 | |
| SCHEMBL23301226 | 0.82 | DDB1 (0.67) | DDB1CRBNGPR119 | |
| SCHEMBL31134539 | 0.82 | DDB1 (0.59) | DDB1CRBNGPR119PDK2 | |
| SCHEMBL31382134 | 0.81 | CRBN (0.63) | DDB1CRBN | |
| SCHEMBL30831006 | 0.81 | DDB1 (0.58) | DDB1CRBNGPR119PDK2 | |
| SCHEMBL30883399 | 0.81 | DDB1 (0.58) | DDB1CRBNGPR119PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
| WO-2023018238-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | DDB1 132/4885CRBN 2136/4885GPR119 4495/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | DDB1 77/4885CRBN 2496/4885GPR119 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.